JP2004509141A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004509141A5 JP2004509141A5 JP2002528195A JP2002528195A JP2004509141A5 JP 2004509141 A5 JP2004509141 A5 JP 2004509141A5 JP 2002528195 A JP2002528195 A JP 2002528195A JP 2002528195 A JP2002528195 A JP 2002528195A JP 2004509141 A5 JP2004509141 A5 JP 2004509141A5
- Authority
- JP
- Japan
- Prior art keywords
- particles
- tap density
- aerosol
- diameter
- density
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 description 29
- 210000004072 Lung Anatomy 0.000 description 8
- 239000000443 aerosol Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 230000002685 pulmonary Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1H-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 210000003456 Pulmonary Alveoli Anatomy 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
Description
【請求項1】 中枢神経系の障害のための救急治療を提供するための有効量の薬物を含有してなる粒子であって、約0.4g/cm3未満のタップ密度を有し、肺系の肺胞領域へ送達されるものである、粒子。
【請求項3】 約0.4g/cm3未満のタップ密度を有するものである請求項2記載の粒子。
【請求項27】 中枢神経系の障害を処置するための有効量のベンゾジアゼピン薬物を含有してなる粒子であって、約0.4g/cm3未満のタップ密度を有し、肺系の肺胞領域へ送達されるものである、粒子。
一態様において、本発明の方法で用いられる粒子は、肺系、特に肺胞または肺深部への治療薬の送達に適した粒子である。好ましい態様において、該粒子は、0.4g/cm3未満のタップ密度を有する。別の好ましい態様では、該粒子は、少なくとも5μm(ミクロン)、好ましくは約5μm〜30μmの幾何学(geometric)直径を有する。さらに別の好ましい態様では、該粒子は、約1μm〜約5μmの空力学的直径を有する。別の態様では、該粒子は、5μmよりも大きい、好ましくは約10μm程度以上の質量メジアン幾何学直径(MMGD)を有する。さらに別の態様では、該粒子は、約1μm〜約5μmの範囲の質量メジアン空力学的直径(MMAD)を有する。好ましい態様では、該粒子は、約1μm〜約3μmの範囲のMMADを有する。
好ましい態様では、本発明の粒子は、約0.4g/cm3未満のタップ密度を有する。約0.4g/cm3未満のタップ密度を有する粒子は、本明細書において、「空気力学的に軽い粒子」と称される。約0.1g/cm3未満のタップ密度を有する粒子がより好ましい。タップ密度は、デュアルプラットホームマイクロプロセッサ制御タップ密度テスター(Dual Platform Microprocessor Controlled Tap Density Tester)(Vankel,NC)またはGeoPycTM装置(Micrometrics Instrument Corp.,Norcross,GA 30093)など(これらに限定されない)の当業者に公知の装置を用いて測定され得る。タップ密度は、エンベロープ質量密度の標準測定値である。タップ密度は、「USPかさ密度およびタップ密度」、米国薬局方協約、Rockville,MD,第10版補遺、4950〜4951、1999の方法を用いて測定できる。低タップ密度に寄与することができる特徴としては、不規則な表面テクスチャーと多孔性構造が挙げられる。
約0.4g/cm3未満のタップ密度、少なくとも約5μmのメジアン直径、および約1μm〜約5μm、好ましくは約1μm〜約3μmの空気力学的直径を有する粒子は、口腔咽頭領域における慣性および重力沈着をより多く免れることができ、気道、特に深肺(deep lung)に標的される。より大きな、より多孔性の粒子は、吸入治療のために現在使用されているようなより小さく密なエーロゾル粒子よりも効率的にエーロゾル化することができるので、それらの使用は好都合である。
当該粒子は、深肺または上気道または中央気道のような気道の選択された領域への局所送達のために、適切な材料、表面粗度、直径およびタップ密度で作製され得る。例えば、上気道送達のためにはより高密度またはより大きな粒子が使用され得るか、あるいは同じまたは異なる治療薬である場合、サンプル中における異なるサイズの粒子の混合物が1回の投与で肺の異なる領域を標的とするように投与され得る。約3〜約5μmの範囲の空気力学的直径を有する粒子が中央気道および上気道への送達にとって好ましい。深肺への送達のためには約1〜約3μmの範囲の空気力学的直径を有する粒子が好ましい。
エーロゾルの慣性嵌入と重力沈降が通常の呼吸条件での気道および肺細葉における主要な沈着機序である。Edwards,D.A.,J.Aerosol Sci.,26:293〜317(1995)。両方の沈着機序の重要性は、粒子(またはエンベロープ)体積ではなくエーロゾルの質量に比例して上昇する。肺におけるエーロゾル沈着部位はエーロゾルの質量によって決定されるので(少なくとも平均空気力学的直径が約1μmをこえる粒子については)、粒子表面の不規則性と粒子の多孔性を高めることによってタップ密度を低下させることは、他の物理的パラメータがすべて等しければ、より大きな粒子エンベロープ体積を肺に送達することができる。
タップ密度が低い粒子は、実際のエンベロープ球体直径に比べて小さな空気力学的直径を有する。空気力学的直径、daerは、式:
[式中、エンベロープ質量ρは、g/cm3の単位である]
によってエンベロープ球体直径、dに関係づけられる(Gonda,I. 「エーロゾル送達における物理−化学的原理(Physico-chemical principles in aerosol delivery)」Topics in Pharmaceutical Sciences 1991より(D.J.A.CrommeliとK.K.Midha編集)、p.95〜117,Stuttgart:Medpharm Scientific Publishers,1992)。ヒト肺の肺胞領域における単分散エーロゾル粒子の最大沈着(約60%)は、約daer=3μmの空気力学的直径について起こる。Heyder,J.ら、J.Aerosol Sci.,17:811〜825(1986)。その小さなエンベロープ質量密度により、最大深肺沈着を示す単分散吸入粉末を含む空気力学的に軽い粒子の実際の直径dは:
[式中、dは常に3μmより大きい]
である。例えば、エンベロープ質量密度、ρ=0.1g/cm3を示す空気力学的に軽い粒子は、9.5μmの大きさのエンベロープ直径を有する粒子について最大沈着を示す。粒子サイズが大きくなると粒子間接着力が低下する。Visser,J.,Powder Technology,58:1〜10。従って、大きな粒子サイズは、より低い食作用損失に寄与することに加えて、エンベロープ質量密度の低い粒子に関して深肺へのエーロゾル適用の効率を高める。
によってエンベロープ球体直径、dに関係づけられる(Gonda,I. 「エーロゾル送達における物理−化学的原理(Physico-chemical principles in aerosol delivery)」Topics in Pharmaceutical Sciences 1991より(D.J.A.CrommeliとK.K.Midha編集)、p.95〜117,Stuttgart:Medpharm Scientific Publishers,1992)。ヒト肺の肺胞領域における単分散エーロゾル粒子の最大沈着(約60%)は、約daer=3μmの空気力学的直径について起こる。Heyder,J.ら、J.Aerosol Sci.,17:811〜825(1986)。その小さなエンベロープ質量密度により、最大深肺沈着を示す単分散吸入粉末を含む空気力学的に軽い粒子の実際の直径dは:
である。例えば、エンベロープ質量密度、ρ=0.1g/cm3を示す空気力学的に軽い粒子は、9.5μmの大きさのエンベロープ直径を有する粒子について最大沈着を示す。粒子サイズが大きくなると粒子間接着力が低下する。Visser,J.,Powder Technology,58:1〜10。従って、大きな粒子サイズは、より低い食作用損失に寄与することに加えて、エンベロープ質量密度の低い粒子に関して深肺へのエーロゾル適用の効率を高める。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/665,252 | 2000-09-19 | ||
US09/665,252 US6514482B1 (en) | 2000-09-19 | 2000-09-19 | Pulmonary delivery in treating disorders of the central nervous system |
US09/877,734 | 2001-06-08 | ||
US09/877,734 US6613308B2 (en) | 2000-09-19 | 2001-06-08 | Pulmonary delivery in treating disorders of the central nervous system |
PCT/US2001/029311 WO2002024158A2 (en) | 2000-09-19 | 2001-09-19 | Pulmonary delivery in treating disorders of the central nervous system |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012144071A Division JP2012180378A (ja) | 2000-09-19 | 2012-06-27 | 中枢神経系の障害の処置における肺送達 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004509141A JP2004509141A (ja) | 2004-03-25 |
JP2004509141A5 true JP2004509141A5 (ja) | 2009-03-05 |
JP5421510B2 JP5421510B2 (ja) | 2014-02-19 |
Family
ID=27099159
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002528195A Expired - Lifetime JP5421510B2 (ja) | 2000-09-19 | 2001-09-19 | 中枢神経系の障害の処置における肺送達 |
JP2012144071A Withdrawn JP2012180378A (ja) | 2000-09-19 | 2012-06-27 | 中枢神経系の障害の処置における肺送達 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012144071A Withdrawn JP2012180378A (ja) | 2000-09-19 | 2012-06-27 | 中枢神経系の障害の処置における肺送達 |
Country Status (10)
Country | Link |
---|---|
US (7) | US6613308B2 (ja) |
EP (2) | EP1318785B1 (ja) |
JP (2) | JP5421510B2 (ja) |
AU (2) | AU9112201A (ja) |
CA (1) | CA2421974C (ja) |
CY (1) | CY1118851T1 (ja) |
DK (1) | DK1318785T3 (ja) |
ES (1) | ES2621549T3 (ja) |
PT (1) | PT1318785T (ja) |
WO (1) | WO2002024158A2 (ja) |
Families Citing this family (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020052310A1 (en) * | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
US7779020B2 (en) * | 2002-03-01 | 2010-08-17 | International Business Machines Corporation | Small-footprint applicative query interpreter method, system and program product |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
CA2307278A1 (en) * | 2000-04-28 | 2001-10-28 | University Of British Columbia | Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine |
FR2812545B1 (fr) * | 2000-08-03 | 2003-03-28 | Air Liquide Sante Int | Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur |
US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
AU2002310074B2 (en) * | 2001-05-24 | 2008-09-04 | Alexza Pharmaceuticals, Inc. | Delivery of compounds for the treatment of migraine through an inhalation route |
WO2002094237A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of beta-blockers through an inhalation route |
WO2002094246A2 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
WO2002094238A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of anti-migraine compounds through an inhalation route |
US20080038363A1 (en) * | 2001-05-24 | 2008-02-14 | Zaffaroni Alejandro C | Aerosol delivery system and uses thereof |
WO2002094242A1 (en) | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan or zolmitriptan through an inhalation route |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
DE60228703D1 (de) * | 2001-05-24 | 2008-10-16 | Alexza Pharmaceuticals Inc | Verabreichung von sedativa-hypnotika durch inhalation |
CA2446904A1 (en) * | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US6805853B2 (en) | 2001-11-09 | 2004-10-19 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
WO2002094232A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of antidepressants through an inhalation route |
WO2002094234A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of opioids through an inhalation route |
AU2002310085B2 (en) * | 2001-05-24 | 2008-09-04 | Alexza Pharmaceuticals, Inc. | Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
DE60227660D1 (de) * | 2001-05-24 | 2008-08-28 | Alexza Pharmaceuticals Inc | Freisetzung von antiemetika auf dem inhalationsweg |
WO2002094244A2 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of benzodiazepines through an inhalation route |
DE10137633A1 (de) * | 2001-08-03 | 2003-02-20 | Boehringer Ingelheim Pharma | Pramipexol zur Behandlung von ADHD |
WO2003057188A1 (en) | 2001-11-21 | 2003-07-17 | Alexza Molecular Delivery Corporation | Delivery of caffeine through an inhalation route |
EP1458360B1 (en) | 2001-12-19 | 2011-05-11 | Novartis AG | Pulmonary delivery of aminoglycosides |
JP2005521695A (ja) * | 2002-03-20 | 2005-07-21 | アドバンスト インハレーション リサーチ,インコーポレイテッド | 肺送達による成長ホルモンの投与方法 |
ES2389156T3 (es) * | 2002-03-20 | 2012-10-23 | Civitas Therapeutics, Inc. | Administración pulmonar de levodopa |
DE60318938T2 (de) | 2002-03-20 | 2009-01-22 | Mannkind Corp., Valencia | Inhalationsgerät |
JP2005529123A (ja) * | 2002-04-24 | 2005-09-29 | リサーチ ディベロップメント ファンデーション | 核転写調節因子NF−κB抑制剤と抗腫瘍薬の相乗効果 |
EP1503744A1 (en) | 2002-05-13 | 2005-02-09 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
US20060193788A1 (en) * | 2002-11-26 | 2006-08-31 | Hale Ron L | Acute treatment of headache with phenothiazine antipsychotics |
CA2489947A1 (en) * | 2002-06-24 | 2003-12-31 | Research Development Foundation | Treatment of human multiple myeloma by curcumin |
EP3308772B8 (en) * | 2002-06-28 | 2021-03-17 | Civitas Therapeutics, Inc. | Inhalable epinephrine |
US20060094785A1 (en) * | 2002-07-12 | 2006-05-04 | Guttuso Jr Thomas J | Use of amino acids for treatment of various conditions |
US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
AU2003294470B2 (en) * | 2002-11-26 | 2009-09-17 | Alexza Pharmaceuticals, Inc. | Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain |
AU2003295823B2 (en) * | 2002-11-26 | 2009-11-05 | Alexza Pharmaceuticals, Inc. | Treatment of headache with antipsychotics delivered by inhalation |
US7550133B2 (en) * | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
CA2515146C (en) * | 2003-02-04 | 2011-12-06 | Chrysalis Technologies Incorporated | Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem |
AU2004231342A1 (en) | 2003-04-14 | 2004-11-04 | Vectura Ltd | Dry power inhaler devices and dry power formulations for enhancing dosing efficiency |
CA2526475A1 (en) | 2003-05-21 | 2004-12-02 | Alexza Pharmaceuticals, Inc. | Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
ES2872350T3 (es) * | 2003-06-13 | 2021-11-02 | Civitas Therapeutics Inc | Polvos farmacéuticos de dosis baja para inhalación |
JP2007503475A (ja) | 2003-08-26 | 2007-02-22 | リサーチ ディベロップメント ファウンデーション | 破骨細胞形成阻害剤およびその使用方法 |
US20050181036A1 (en) * | 2003-08-26 | 2005-08-18 | Research Development Foundation | Aerosol delivery of curcumin |
US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
MXPA06014567A (es) | 2004-06-18 | 2007-07-24 | Novartis Vaccines & Diagnostic | Metodo para el tratamiento de infecciones endobronquiales. |
WO2006023849A2 (en) | 2004-08-20 | 2006-03-02 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
HUE025151T2 (en) | 2004-08-23 | 2016-01-28 | Mannkind Corp | Diceto-piperazine salts for drug delivery |
AU2005290238A1 (en) | 2004-09-18 | 2006-04-06 | Department Of Veterans Affairs | Therapeutic agents trageting the NCCa-ATP channel and methods of use thereof |
ATE487484T1 (de) | 2004-09-18 | 2010-11-15 | Univ Maryland | Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
US20060134009A1 (en) * | 2004-12-16 | 2006-06-22 | Daniel Deaver | Low dose corticosteroid powders for inhalation |
JP5749881B2 (ja) | 2005-04-22 | 2015-07-15 | ユニヴェルシテ デ ジュネーブ | ポリラクチド組成物およびその使用 |
AU2006290870B2 (en) | 2005-09-14 | 2013-02-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
MX2008010721A (es) | 2006-02-22 | 2008-09-01 | Mannkind Corp | Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo. |
EP3103451A1 (en) | 2007-01-12 | 2016-12-14 | University of Maryland, Baltimore | Targetting ncca-atp channel for organ protection following ischemic episode |
US20080275030A1 (en) | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
EP2120580B1 (en) | 2007-02-02 | 2017-12-27 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
WO2008098160A1 (en) | 2007-02-09 | 2008-08-14 | University Of Maryland, Baltimore | Antagonists of a non-selective cation channel in neural cells |
WO2008097664A1 (en) | 2007-02-11 | 2008-08-14 | Map Pharmaceuticals, Inc. | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
EP2121088B1 (en) | 2007-03-09 | 2016-07-13 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US8557867B2 (en) | 2007-06-22 | 2013-10-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Inhibitors of NCCa-ATP channels for therapy |
JP2010533181A (ja) * | 2007-07-13 | 2010-10-21 | アボツト・バイオテクノロジー・リミテツド | TNFα阻害剤の肺投与のための方法及び組成物 |
GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
GB2454480A (en) * | 2007-11-07 | 2009-05-13 | Vectura Group Plc | Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders |
US20090247537A1 (en) * | 2008-03-25 | 2009-10-01 | William Dale Overfield | Methods for preventing or treating bruxism using dopaminergic agents |
KR101548092B1 (ko) | 2008-06-13 | 2015-08-27 | 맨카인드 코포레이션 | 건조 분말 흡입기 및 약물 투여 시스템 |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
CN102065942B (zh) | 2008-06-20 | 2013-12-11 | 曼金德公司 | 用于对吸入工作进行实时描绘的交互式设备和方法 |
TWI494123B (zh) | 2008-08-11 | 2015-08-01 | Mannkind Corp | 超快起作用胰島素之用途 |
CN109010254A (zh) * | 2008-08-15 | 2018-12-18 | 硬木药品公司 | 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂 |
JP2012502915A (ja) | 2008-09-15 | 2012-02-02 | バイオビスタ インコーポレイテッド | てんかんを治療する組成物及び方法 |
EP2719380A3 (en) | 2008-09-16 | 2014-07-30 | University of Maryland, Baltimore | SUR1 inhibitors for therapy |
US8349899B1 (en) | 2008-12-03 | 2013-01-08 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
US8765817B1 (en) | 2008-12-03 | 2014-07-01 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
US8555875B2 (en) | 2008-12-23 | 2013-10-15 | Map Pharmaceuticals, Inc. | Inhalation devices and related methods for administration of sedative hypnotic compounds |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
WO2010105094A1 (en) | 2009-03-11 | 2010-09-16 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
EP2228054A1 (en) * | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
CA2754691C (en) | 2009-03-26 | 2019-07-30 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
ES2598006T3 (es) | 2009-04-24 | 2017-01-24 | Vanderbilt University | Anticuerpos anti-TGF-beta para la inducción del crecimiento óseo |
US8734845B2 (en) | 2009-06-12 | 2014-05-27 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
PT2456304E (pt) | 2009-07-24 | 2015-10-12 | Baylor College Medicine | Métodos de modulação de ácidos de cadeia ramificada e utilização dos mesmos |
JP2013501071A (ja) * | 2009-08-06 | 2013-01-10 | アイロンウッド ファーマシューティカルズ, インコーポレイテッド | リナクロチドを含む処方物 |
WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
WO2011103311A2 (en) | 2010-02-17 | 2011-08-25 | Ironwood Pharmaceuticals, Inc | Treatments for gastrointestinal disorders |
EP2582421A1 (en) | 2010-06-21 | 2013-04-24 | MannKind Corporation | Dry powder drug delivery system and methods |
LT2603232T (lt) | 2010-08-11 | 2020-01-27 | Ironwood Pharmaceuticals, Inc. | Stabilios linaklotido vaisto formos |
EP4050109A1 (en) | 2010-08-18 | 2022-08-31 | Fred Hutchinson Cancer Center | Agents for use in treating facioscapulohumeral dystrophy (fshd) |
WO2012030645A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
EP2621484A1 (en) | 2010-09-29 | 2013-08-07 | Pulmatrix, Inc. | Monovalent metal cation dry powders for inhalation |
US8925726B2 (en) | 2011-04-01 | 2015-01-06 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
EP3628325A1 (en) | 2011-07-22 | 2020-04-01 | The University of Chicago | Treatments for migraine and related disorders |
ES2614864T3 (es) | 2011-08-17 | 2017-06-02 | Ironwood Pharmaceuticals, Inc. | Tratamientos para trastornos gastrointestinales |
US9655905B2 (en) | 2011-09-14 | 2017-05-23 | King Abdullah University Of Science And Technology | Treatment of sickle cell disease |
EP2758519B1 (en) | 2011-09-21 | 2017-03-29 | King Abdullah University Of Science And Technology | Didemnin biosynthetic gene cluster in tistrella mobilis |
US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
IN2014DN03093A (ja) | 2011-10-24 | 2015-05-15 | Mannkind Corp | |
BR112014018110B1 (pt) | 2012-01-23 | 2022-06-07 | Sage Therapeutics, Inc | Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina |
AU2013221448B2 (en) | 2012-02-16 | 2017-02-23 | The University Of Toledo | Xenoantigen-displaying anti-cancer vaccines and method of making |
WO2013130422A1 (en) | 2012-02-27 | 2013-09-06 | Biovista, Inc. | Compositions and methods for treating mitochondrial diseases |
CN104487075A (zh) | 2012-02-29 | 2015-04-01 | 普马特里克斯公司 | 可吸入干粉剂 |
AR092821A1 (es) | 2012-04-20 | 2015-05-06 | Sucampo Ag | Conjugado de derivado de acido graso-polimero |
AU2013266232B2 (en) | 2012-05-23 | 2017-08-03 | The Ohio State University | Lipid nanoparticle compositions for antisense oligonucleotides delivery |
KR102264177B1 (ko) | 2012-07-12 | 2021-06-11 | 맨카인드 코포레이션 | 건조 분말 약물 전달 시스템 및 방법 |
US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
EP3957309A1 (en) | 2012-08-21 | 2022-02-23 | Sage Therapeutics, Inc. | Preparation of a composition comprising allopregnanolone and sulfobutylether-beta-cyclodextrin |
NZ708415A (en) * | 2012-10-22 | 2018-11-30 | Civitas Therapeutics Inc | Reducing inter-patient variability of levodopa plasma concentrations |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
US8545878B1 (en) * | 2012-11-09 | 2013-10-01 | Civitas Therapeutics, Inc. | Capsules containing high doses of levodopa for pulmonary use |
BR112015010601B1 (pt) * | 2012-11-09 | 2022-07-19 | Civitas Therapeutics, Inc. | Composição farmacêutica e uso da composição |
ES2973320T3 (es) | 2012-11-30 | 2024-06-19 | Univ California | Alopregnanolona para tratar, reducir o mitigar los síntomas de la depresión posparto |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
FR3000392B1 (fr) * | 2012-12-27 | 2015-03-27 | Virbac | Nouvelles compositions pharmaceutiques veterinaires et leur procede de preparation |
WO2014160339A1 (en) | 2013-03-13 | 2014-10-02 | Board Of Regents, The University Of Texas System | Compounds for treating inflammatory and hyperproliferative diseases |
AU2014228415B2 (en) | 2013-03-15 | 2018-08-09 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
JP6675974B2 (ja) * | 2013-03-26 | 2020-04-08 | オプティノーズ アズ | 経鼻投与 |
CA2907566C (en) | 2013-04-01 | 2023-08-22 | Pulmatrix, Inc. | Tiotropium dry powders |
CN105473133A (zh) | 2013-04-30 | 2016-04-06 | 欧缇托匹克公司 | 干粉制剂及使用方法 |
BR122019026637B1 (pt) | 2013-07-18 | 2023-09-26 | Mannkind Corporation | Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco |
US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
WO2015084625A1 (en) | 2013-12-02 | 2015-06-11 | Baylor College Of Medicine | Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose |
CA2977083A1 (en) * | 2014-02-20 | 2015-08-27 | Kambiz Yadidi | Dry powder formulations for inhalation |
WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
US9693994B2 (en) | 2014-04-09 | 2017-07-04 | Research Development Foundation | Class IIa HDAC inhibitors for the treatment of infection |
AU2014391721B2 (en) * | 2014-04-21 | 2020-07-16 | Merz Pharmaceuticals, Llc | Rapid relief of motor fluctuations in Parkinson's Disease |
US10278986B2 (en) | 2014-08-14 | 2019-05-07 | The Regents Of The University Of Colorado, A Body Corporate | Antibody-siRNA conjugates and uses therefor |
JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
DK3212212T3 (da) | 2014-10-31 | 2020-12-21 | Univ Monash | Pulverformulering |
WO2016073184A1 (en) | 2014-11-04 | 2016-05-12 | Dana Farber Cancer Institute, Inc. | Compositions and methods for treating multiple myeloma |
EP3285792B1 (en) | 2015-04-20 | 2020-11-04 | The Board of Regents of The University of Texas System | Clec11a is a bone growth agent |
AU2016257729A1 (en) * | 2015-05-01 | 2017-11-09 | Civitas Therapeutics, Inc. | Zolmitriptan powders for pulmonary delivery |
US10962551B2 (en) | 2015-06-17 | 2021-03-30 | The Johns Hopkins University | TDP-43 in degenerative disease |
CA2991108A1 (en) | 2015-07-02 | 2017-01-05 | Civitas Therapeutics, Inc. | Triptan powders for pulmonary delivery |
US10695322B2 (en) | 2016-01-29 | 2020-06-30 | The Johns Hopkins University | Inhibitors of bacterial growth |
US11040025B2 (en) | 2016-02-17 | 2021-06-22 | The Johns Hopkins University | Oxazolidinone for treatment of infections with Mycobacterium tuberculosis |
WO2017147370A1 (en) | 2016-02-24 | 2017-08-31 | The Johns Hopkins University | Novel antiviral proteins and their uses in therapeutic methods |
US10888549B2 (en) | 2016-03-07 | 2021-01-12 | The Johns Hopkins University | Pharmaceutical agents targeting cancer stem cells |
MX2018010902A (es) | 2016-03-08 | 2019-03-06 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos. |
MX2018010850A (es) | 2016-03-10 | 2019-05-15 | Univ Johns Hopkins | Métodos para producir proteínas de fusión de toxina diftérica monoméricas y libres de agregados y usos terapéuticos. |
US11203626B2 (en) | 2016-03-10 | 2021-12-21 | The Johns Hopkins University | Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses |
CN109414417A (zh) | 2016-03-17 | 2019-03-01 | 约翰·霍普金斯大学 | 通过paris的法尼基化预防或治疗帕金森症的方法 |
WO2017173055A1 (en) | 2016-03-30 | 2017-10-05 | The Johns Hopkins University | Olfr90 specificity and methods of detection |
WO2017189483A1 (en) | 2016-04-25 | 2017-11-02 | The Johns Hopkins University | Znt8 assays for drug development and pharmaceutical compositions |
US10568894B2 (en) | 2016-06-03 | 2020-02-25 | Otitopic Inc. | Dry powder formulations for inhalation |
US11149275B2 (en) | 2016-10-10 | 2021-10-19 | The Johns Hopkins University | Device and method to treat esophageal disorders |
JP7379154B2 (ja) | 2016-12-09 | 2023-11-14 | アレクザ・ファーマシューティカルズ・インコーポレイテッド | てんかんを処置する方法 |
US10434089B2 (en) | 2017-01-25 | 2019-10-08 | The Johns Hopkins University | Avibactam and carbapenems antibacterial agents |
WO2019014044A1 (en) | 2017-07-12 | 2019-01-17 | The Johns Hopkins University | ZNT8 AUTO-ANTIGEN BASED ON PROTEOLIPOSOMES FOR THE DIAGNOSIS OF TYPE 1 DIABETES |
US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
MX2020002769A (es) | 2017-09-22 | 2020-07-20 | Otitopic Inc | Composiciones de polvo seco con estearato de magnesio. |
EP3710029A4 (en) | 2017-11-16 | 2021-08-18 | University of Maine System Board of Trustees | COMPOSITIONS AND METHODS FOR MODULATING MIGRATION AND ANGIOGENESIS OF ENDOTHELIAL CELLS |
US11246857B2 (en) | 2017-12-14 | 2022-02-15 | The Johns Hopkins University | Anti-fungal inhibitors |
EP3837286A4 (en) | 2018-08-16 | 2022-08-10 | The Johns Hopkins University | ANTIBODIES TO HUMAN ZNT8 |
EP3921029A4 (en) | 2019-02-07 | 2022-12-07 | Baylor College of Medicine | PERIOSTEAL SKELETAL STEM CELLS IN BONE REPAIR |
US11717506B2 (en) | 2019-05-07 | 2023-08-08 | The Johns Hopkins University | Neuroprotective compounds for amyotrophic lateral sclerosis |
US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
JPS6122019A (ja) | 1984-07-06 | 1986-01-30 | Tomio Konno | 吸入細胞活性薬品とその使用方法 |
GB8501015D0 (en) | 1985-01-16 | 1985-02-20 | Riker Laboratories Inc | Drug |
ATE78158T1 (de) | 1985-05-22 | 1992-08-15 | Liposome Technology Inc | Verfahren und system zum einatmen von liposomen. |
JP2573275B2 (ja) * | 1986-03-10 | 1997-01-22 | ブルグハルト,クルト | 薬学的製剤及びその製造法 |
IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
US6048857A (en) | 1989-10-17 | 2000-04-11 | Ellinwood, Jr.; Everett H. | Dosing method of administering medicaments via inhalation administration |
US5118494A (en) | 1990-03-23 | 1992-06-02 | Minnesota Mining And Manufacturing Company | Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
AU7908791A (en) | 1990-05-08 | 1991-11-27 | Liposome Technology, Inc. | Direct spray-dried drug/lipid powder composition |
US5166202A (en) | 1990-09-19 | 1992-11-24 | Trustees Of The University Of Pennsylvania | Method for the treatment of panic disorder |
GB9101592D0 (en) | 1991-01-24 | 1991-03-06 | Glaxo Group Ltd | Compositions |
ATE179605T1 (de) * | 1991-02-09 | 1999-05-15 | B S D Bio Science Dev Snc Di O | Antireaktive antiasthmatische wirkung von acetylsalicylsäure durch inhalation |
DE69232003T2 (de) | 1991-09-18 | 2002-04-25 | Glaxo Group Ltd., Greenford | Benzanilidderivate als 5-HT1D-Antagonisten |
US5457100A (en) | 1991-12-02 | 1995-10-10 | Daniel; David G. | Method for treatment of recurrent paroxysmal neuropsychiatric |
US5756071A (en) | 1992-06-03 | 1998-05-26 | Arrowdean Limited | Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier |
US5284133A (en) | 1992-07-23 | 1994-02-08 | Armstrong Pharmaceuticals, Inc. | Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means |
AU5171293A (en) | 1992-10-14 | 1994-05-09 | Regents Of The University Of Colorado, The | Ion-pairing of drugs for improved efficacy and delivery |
US5354885A (en) * | 1992-12-24 | 1994-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Process for preparing ethyl ester of L-DOPA |
MX9603936A (es) | 1994-03-07 | 1997-05-31 | Inhale Therapeutic Syst | Metodos y composiciones para el suministro pulmonar de insulina. |
CA2190502A1 (en) * | 1994-05-18 | 1995-11-23 | Robert M. Platz | Methods and compositions for the dry powder formulation of interferons |
CA2152684A1 (en) | 1994-07-01 | 1996-01-02 | Richard Anthony Henry | Aerosol delivery of midazolam |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
GB9606188D0 (en) * | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
US5875776A (en) | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US6503480B1 (en) * | 1997-05-23 | 2003-01-07 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6103270A (en) | 1996-06-07 | 2000-08-15 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
ZA9711732B (en) * | 1996-12-31 | 1998-12-28 | Quadrant Holdings Cambridge | Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery |
EP0954282B1 (en) | 1997-01-16 | 2005-01-19 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5958902A (en) | 1997-04-16 | 1999-09-28 | Wisconsin Alumni Research Foundation | Method and composition for treating sleep apnea |
US6284282B1 (en) * | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
BR0010984A (pt) | 1999-05-27 | 2002-04-30 | Acusphere Inc | Matrizes porosas de medicamento e processos para fabricação das mesmas |
US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US7090830B2 (en) * | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
WO2002094243A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route |
-
2001
- 2001-06-08 US US09/877,734 patent/US6613308B2/en not_active Expired - Lifetime
- 2001-09-19 WO PCT/US2001/029311 patent/WO2002024158A2/en active IP Right Grant
- 2001-09-19 JP JP2002528195A patent/JP5421510B2/ja not_active Expired - Lifetime
- 2001-09-19 AU AU9112201A patent/AU9112201A/xx active Pending
- 2001-09-19 DK DK01971210.8T patent/DK1318785T3/en active
- 2001-09-19 AU AU2001291122A patent/AU2001291122B2/en not_active Expired
- 2001-09-19 EP EP01971210.8A patent/EP1318785B1/en not_active Expired - Lifetime
- 2001-09-19 EP EP15201016.1A patent/EP3061453A1/en not_active Ceased
- 2001-09-19 CA CA2421974A patent/CA2421974C/en not_active Expired - Lifetime
- 2001-09-19 ES ES01971210.8T patent/ES2621549T3/es not_active Expired - Lifetime
- 2001-09-19 PT PT1971210T patent/PT1318785T/pt unknown
-
2003
- 2003-05-20 US US10/441,968 patent/US6979437B2/en not_active Expired - Lifetime
-
2004
- 2004-01-21 US US10/762,200 patent/US20040228923A1/en not_active Abandoned
- 2004-07-21 US US10/895,577 patent/US20040265242A1/en not_active Abandoned
-
2008
- 2008-07-02 US US12/166,704 patent/US20090162441A1/en not_active Abandoned
-
2011
- 2011-09-13 US US13/231,405 patent/US20120087952A1/en not_active Abandoned
-
2012
- 2012-06-27 JP JP2012144071A patent/JP2012180378A/ja not_active Withdrawn
-
2014
- 2014-01-10 US US14/152,492 patent/US20140193501A1/en not_active Abandoned
-
2017
- 2017-03-21 CY CY20171100358T patent/CY1118851T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004509141A5 (ja) | ||
JP2005504715A5 (ja) | ||
Crowder et al. | Fundamental effects of particle morphology on lung delivery: predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development | |
US5642728A (en) | System for dispensing pharmaceutically active compounds | |
JP2001517691A5 (ja) | ||
US6250300B1 (en) | System for dispensing pharmaceutically active compounds | |
JP4103939B2 (ja) | ドライパウダー吸入器に用いられるパウダー | |
Johnson et al. | Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma: efficacy and pulmonary deposition | |
KR100652532B1 (ko) | 유동 저항이 조절된 에어로졸화 활성 약물의 송달 | |
TWI228998B (en) | Method and device for delivering an active agent to the lungs | |
Barry et al. | In vitro comparison of the amount of salbutamol available for inhalation from different formulations used with different spacer devices | |
Lee et al. | In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases | |
CA2421974A1 (en) | Pulmonary delivery in treating disorders of the central nervous system | |
Chew et al. | In vitro aerosol performance and dose uniformity between the Foradile® Aerolizer® and the Oxis® Turbuhaler® | |
AU2018253538B2 (en) | Levodopa formulations for rapid relief of parkinson's disease | |
Weuthen et al. | In vitro testing of two formoterol dry powder inhalers at different flow rates | |
Gonda | Targeting by deposition | |
Ali et al. | Measurements of electrodynamic effects on the deposition of MDI and DPI aerosols in a replica cast of human oral–pharyngeal–laryngeal airways | |
Zanen et al. | Targeting the lungs with therapeutic aerosols | |
Everard et al. | An alternative aerosol delivery system for amiloride. | |
Gilani et al. | Influence of formulation variables and inhalation device on the deposition profiles of cromolyn sodium dry powder aerosols | |
US20080107740A1 (en) | Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders | |
KR102237007B1 (ko) | 레보도파 혈장 농도의 환자간 변산도의 감소 | |
CN102000089A (zh) | 一种以环索奈德与阿福特罗为活性成分的复方制剂 | |
Benson et al. | Optimisation of Drug Delivery: 5. Pulmonary Drug Delivery |